Saturday 17 October 2026
Export MYGN’s income statement to Excel — free account
Myriad Genetics, Inc.
MYGN Healthcare Diagnostics & Research
Myriad Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $824.5 million, down 1.56% from fiscal 2024. In the quarter to June 2026, revenue fell 10.5%, EPS grew 87.1%, free cash flow grew 43.9% and total debt rose 103.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.98
0.37
−8.51%
Follow MYGN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jun '22 | Dec '21 | Jun '21 | Dec '20 | Jun '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | — | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.69 | 1.48 | 2.09 | 1.81 | 2.17 | 3.12 | 3.17 | 2.30 | 1.32 | 2.49 |
Altman Z-Score |
(1.52) | 1.83 | 1.93 | 2.13 | 1.70 | 3.69 | 3.10 | 1.53 | 0.93 | — |
Altman Z″-Score (non-manufacturers) |
(5.88) | (0.10) | (0.13) | 1.94 | 0.73 | 2.68 | 1.81 | 1.23 | 1.33 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,588.00 | 36.43 | 29.09 | 16.72 | 24.06 |
P/Operating CF |
53.73 | 188.20 | (28.76) | (168.49) | (29.39) | (226.61) | (536.54) | 20.07 | 28.20 | (1,066.27) |
Beneish M-Score |
(5.42) | (3.06) | (3.14) | — | — | — | — | — | — | — |
P/B ratio |
1.55 | 1.77 | 2.01 | 1.39 | 1.54 | 2.22 | 2.62 | 1.67 | 0.92 | 1.88 |
Price to Tangible BV |
3.49 | 8.15 | 10.75 | 5.61 | 4.46 | 6.63 | 10.02 | 0.00 | 0.00 | 129.04 |
EV/Sales |
0.73 | 1.43 | 1.98 | 1.86 | 2.02 | 2.76 | 3.22 | 2.44 | 1.36 | 2.61 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.77 | 7.95 |
EV/Operating CF |
332.88 | (137.62) | (13.42) | (11.85) | (9.35) | 102.47 | 29.49 | 25.65 | 14.28 | 21.75 |
EV/FCF |
(23.41) | (31.18) | (8.08) | (8.31) | (8.25) | 3,176.67 | 37.00 | 30.83 | 17.13 | 25.21 |
Quick Ratio |
1.98 | 1.36 | 1.64 | 1.58 | 1.60 | 2.11 | 2.11 | 1.65 | 1.96 | — |
Current Ratio |
2.49 | 1.82 | 2.01 | 2.00 | 2.01 | 2.37 | 2.38 | 2.67 | 2.26 | — |
Net Debt/EBITDA |
2.11 | 11.02 | 0.52 | 1.62 | (0.26) | 2.69 | 5.29 | (1.23) | (0.11) | 0.00 |
Debt/Assets |
16.97% | 3.85% | 3.36% | 0.00% | 9.95% | 0.00% | 5.59% | 15.84% | 15.98% | 0.00% |
Debt/Equity |
0.33 | 0.06 | 0.05 | 0.00 | 0.15 | 0.00 | 0.08 | 0.26 | 0.24 | — |
Asset Turnover |
0.95 | 0.77 | 0.64 | 0.54 | 0.51 | 0.51 | 0.49 | 0.45 | 0.43 | 1.09 |
Operating CF/Net income |
0.00 | 0.07 | 0.42 | 0.95 | 0.96 | (0.68) | (0.62) | (0.30) | (0.30) | 18.20 |
Capex/Depreciation |
(0.07) | (0.25) | (1.18) | (0.65) | 0.00 | (0.28) | 0.00 | (0.06) | (0.06) | (0.12) |
Interest Coverage |
(36.88) | (44.11) | (88.76) | (43.94) | (91.00) | (28.86) | (356.86) | (21.45) | (21.45) | 0.63 |
| (68.45%) | (17.15%) | (31.55%) | (12.64%) | (12.08%) | (2.81%) | (2.94%) | (22.18%) | (19.88%) | 0.00% | |
| (42.20%) | (11.71%) | (22.45%) | (8.90%) | (8.49%) | (1.99%) | (1.92%) | (14.13%) | (13.45%) | 0.59% | |
ROIC |
(71.53%) | (12.09%) | (23.63%) | (11.40%) | 0.00% | (18.93%) | 0.00% | (15.16%) | (15.66%) | 0.00% |
Return on Tangible Assets |
(116.98%) | (50.66%) | (95.16%) | (50.72%) | (34.46%) | (8.40%) | (6.70%) | (70.20%) | (89.99%) | 0.00% |
Average Days of Receivables |
51.04 | 52.82 | 55.39 | 54.66 | 54.88 | 48.25 | 48.10 | 51.15 | 40.58 | 0.00 |
Research and Development Expense of Revenue |
12.95% | 13.54% | 11.78% | 12.59% | 12.59% | 11.86% | 11.86% | 12.09% | 12.09% | 10.09% |
Selling, General and Administrative Expense of Revenue |
65.20% | 66.86% | 76.06% | 75.87% | 69.02% | 77.87% | 70.27% | 79.44% | 79.44% | 65.40% |
Intangible Assets out of Total Assets |
0.29 | 0.53 | 0.56 | 0.56 | 0.51 | 0.49 | 0.45 | 0.64 | 0.66 | 0.00 |
Share Based Compensation of Revenue |
4.27% | 5.95% | 5.40% | 5.62% | 0.00% | 5.26% | 0.00% | 3.95% | 3.95% | 3.94% |
Graham Net Nets |
(0.01) | (0.02) | (0.03) | (0.03) | 0.07 | 0.06 | 0.03 | (0.10) | (0.18) | (0.07) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(64.08%) | (10.28%) | (16.84%) | (9.11%) | (1.27%) | (1.34%) | (4.48%) | (15.58%) | (23.63%) | (1.32%) |
Free Cash Flow Yield |
(4.50%) | (3.09%) | (11.71%) | (12.33%) | (11.25%) | 0.03% | 2.74% | 3.44% | 5.98% | 4.16% |
Revenue per Share |
8.90 | 9.25 | 9.10 | 8.42 | 8.42 | 8.85 | 8.85 | 8.59 | 8.59 | 11.58 |
Operating CF per Share |
0.02 | (0.10) | (1.34) | (1.32) | (1.33) | 0.24 | 0.22 | 0.82 | 0.82 | 1.14 |
Capex per Share |
(0.30) | (0.33) | (0.89) | (0.56) | 0.00 | (0.23) | 0.00 | (0.14) | (0.14) | (0.12) |
Free Cash Flow per Share |
(0.28) | (0.42) | (2.22) | (1.88) | (1.33) | 0.01 | 0.22 | 0.68 | 0.68 | 1.02 |
Cash per Share |
1.62 | 1.13 | 1.70 | 1.43 | 1.45 | 4.34 | 4.36 | 2.03 | 2.93 | 0.00 |
Shareholders Equity per Share |
3.97 | 7.74 | 9.46 | 10.99 | 10.99 | 12.41 | 12.41 | 11.86 | 12.36 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.97 | 7.74 | 9.46 | 10.99 | 10.99 | 12.41 | 12.41 | 11.86 | 12.36 | 0.00 |
Free Cash Flow |
(25.60) | (38.40) | (184.20) | (151.60) | (107.00) | 0.60 | 17.00 | 50.50 | 50.50 | 75.10 |
Working Capital |
198.80 | 133.90 | 157.70 | 137.40 | 138.00 | 280.50 | 281.00 | 243.50 | 184.70 | — |
Capital Expenditures |
(27.40) | (29.70) | (73.30) | (45.30) | (45.30) | (18.00) | (18.00) | (10.20) | (10.20) | (8.60) |
Net Current Asset Value |
(6.00) | (28.50) | (49.70) | (38.30) | (156.00) | 131.90 | 39.00 | (148.40) | (154.70) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.04 | 0.10 | 0.07 | 0.00 | 0.03 | 0.00 | 0.02 | 0.02 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.61 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.27 | 1.00 | 0.52 | 0.83 | 0.34 | 1.49 | 0.60 | 4.22 | 4.64 | 0.00 |
Cash ROIC |
(4.02%) | (4.55%) | (19.14%) | (15.15%) | (9.44%) | 0.05% | 1.23% | 4.02% | 3.71% | 0.00% |
Accounts Receivable Turnover |
6.97 | 7.11 | 6.98 | 6.66 | 7.02 | 7.58 | 7.65 | 7.96 | 6.09 | 0.00 |
Accounts Payable Turnover |
7.96 | 8.68 | 8.65 | 6.99 | 8.30 | 6.63 | 9.83 | 8.82 | 6.77 | 0.00 |
Inventory Turnover |
8.53 | 10.19 | 11.22 | 10.07 | 13.77 | 13.04 | 11.80 | 6.62 | 6.15 | 0.00 |
Average Days of Payables |
44.17 | 46.75 | 39.87 | 52.04 | 43.54 | 54.68 | 44.10 | 40.21 | 42.56 | 0.00 |
Days of Inventory on Hand |
45.05 | 39.80 | 34.00 | 36.32 | 30.03 | 28.26 | 22.05 | 53.15 | 57.07 | 0.00 |
Average Receivables |
118.25 | 117.75 | 107.95 | 101.80 | 96.65 | 91.15 | 90.25 | 80.25 | 104.80 | — |
Average Payables |
31.15 | 29.05 | 27.30 | 28.90 | 29.30 | 29.80 | 25.25 | 21.10 | 27.50 | — |
Average Inventory |
29.05 | 24.75 | 21.05 | 20.05 | 17.65 | 15.15 | 21.05 | 28.10 | 30.25 | — |
Average Assets |
867.10 | 1,087.05 | 1,172.60 | 1,257.85 | 1,318.85 | 1,367.35 | 1,416.40 | 1,411.70 | 1,483.65 | 781.35 |
Average Common Equity |
534.55 | 742.15 | 834.50 | 885.90 | 926.90 | 967.90 | 924.50 | 899.60 | 1,003.55 | — |
Columns are period end dates